Trial Profile
A Phase I Study of BMS-986299 as Monotherapy and in Combination With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Jul 2023
Price :
$35
*
At a glance
- Drugs BMS-986299 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Advanced breast cancer; Anal cancer; Bladder cancer; Chondrosarcoma; Lung cancer; Malignant melanoma; Oropharyngeal cancer; Skin cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 17 May 2022 Status changed from recruiting to discontinued.
- 19 Nov 2021 Planned number of patients changed from 117 to 127.